The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.

BACKGROUND Although chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only… CONTINUE READING